NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-.

International Normalized Ratio (INR)

Authors
Sufana Shikdar1; Priyanka T. Bhattacharya2.

Affilations
1 Mercy Catholic Medical Center
2 University of Pennsylvania

Last Update: October 27, 2018.

Introduction
International normalized ratio (INR) is the preferred test of choice for
patients taking vitamin K antagonists (VKA). It can also be used to assess the
risk of bleeding or the coagulation status of the patients. Patients taking oral
anticoagulants are required to monitor INR to adjust the VKA doses
because these vary between patients. The INR is derived from prothrombin
time (PT) which is calculated as a ratio of the patient’s PT to a control PT
standardized for the potency of the thromboplastin reagent developed by
the World Health Organization (WHO) using the following formula:
 INR = Patient PT ÷ Control PT
PT, the time in seconds, is measured in plasma to form a clot in the presence
of sufficient concentration of calcium and tissue thromboplastin by activating
coagulation via the extrinsic pathway. The reference values for INR take into
account in PT measurement in device related variations, type of reagents
used, and sensitivity differences in the TF activator. INR value is
dimensionless and ranges from a score of 2.0 to 3.0. Optimizing the patient’s
INR therapeutic range can be challenging as narrow therapeutic range had
been seen in VKAs and can be affected by patient's characteristics, co-morbid
conditions, diet, and other drug interactions. Patients are monitored every 3–4
weeks or less at the thrombosis centers (TC), point-of-care (POC) clinics, or
in the home setting.

Specimen Collection
Conventional coagulation testing (CCT) can be performed in the laboratory
setting to measure PT/INR. However, given the higher CCT turnaround time
including collection, transportation, and processing of blood samples, Point-
of-care coagulation test (POCT) also known as “bedside testing” or “near-
patient testing" has been developed. It can be performed at or near the
patients with the advantage of shorter turnaround time and improved clinical
outcome. POC devices are used in practitioner offices, long-term care
facilities, pharmacies, or for patient self-testing or self-management. Potential
advantages of POC devices include improved convenience to patients, better
treatment adherence, frequent measurement and fewer thromboembolic and
bleeding complications. However, POC devices tend to overestimate low
INR values and underestimate high INR values. Patient with antiphospholipid
antibodies have been found to have higher error rate in INR determination. In
additon, apart from adherence and treatment satisfaction some patient found
to be more anxious about the PT/INR monitoring.

Procedures
It is recommended by the Clinical and Laboratory Standard Institutes (2017)
that the blood specimens for INR/PT testing in the laboratory setting should
be collected from venous blood and it is directly obtained into a tube with a
light blue top. The tube contains an anticoagulant. The acceptable
anticoagulant is the concentration of sodium citrate 3.2%. The tubes must be
filled to within 90% of the full collection volume. The tube should be then
inverted a few times, gently and as soon as possible, for proper mixing with
the anticoagulant. The total time between sample collection and testing
should not exceed 24 hours.
Providers should be vigilant if the specimen is taken from a vascular-assisted
device because there may be possible heparin contamination that may
interfere with INR reliability. On the other hand, capillary whole blood can
be obtained from POC-PT systems by a fingerstick which is then applied to a
test strip or cartridge. The INR value from POCT is considered acceptable if
it does not exceed plus or minus 0.5 INR units by the reference laboratory
INR value.

Indications
The indications for obtaining an INR value are:
1. Bleeding diathesis in patients with coagulation factors deficiency
(fibrinogen and factors II, V, VII, or X, or a combined deficiency) in the
extrinsic pathway
2. Disseminated intravascular coagulation (DIC)
3. Baseline sample collection before starting anticoagulation
4. Monitoring the efficacy and safety while the patients are on warfarin
due to clinical conditions with an increased risk of thrombosis such
as mechanical heart valves, persistant atrial fibrillation, venous
thromboembolism, stroke, and peripheral arterial disease
5. Test for liver synthetic function and to calculate the model for end-
stage liver diseases (MELD) score in end-stage liver disease
INR monitoring is most commonly required for the patients who are on
warfarin, a vitamin K antagonist. The dose of warfarin is adapted based on
INR scores so that it remains in the therapeutic range to prevent thrombosis
from subtherapeutic INR or hemorrhagic complications from
supratherapeutic INR. The anticoagulant effect of warfarin indicated by
an INR in the target range also guides us when to discontinue heparin.

Potential Diagnosis
The INR is commonly used as a surrogate for the PT value. PT/INR can be
prolonged in:
1. VKAs: Warfarin inhibits the gamma-carboxylation of the vitamin K-
dependent factors, including factors II (prothrombin), VII, IX, and X.
The full anticoagulation effect is reflected approximately one week
after administration of warfarin as the factors with the shortest half-
life (factor VII) is initially depleted, but the factors with a longer half-
life (e.g., prothrombin) takes a longer time to be depleted.
 2. Other anticoagulants: Heparins (unfractionated or low molecular
weight), direct factor Xa inhibitor administration (rivaroxaban,
apixaban, edoxaban),direct thrombin inhibitor administration
(argatroban, dabigatran), and fondaparinux can cause prolongation of
PT and the aPTT by acting on the common pathway factors.
3. Liver dysfunction: Liver synthesized both vitamin K-dependent and
vitamin K-independent clotting factors. Also, warfarin metabolized in
the liver. Thus, the liver disease is associated with prolongation of
PT/INR. However, even with elevated PT/INR, these patients are not
"auto-anticoagulated," because they often reflect homeostatic
abnormalities in the coagulation factors and thus increase thrombotic
risk.
4. Vitamin K deficiency: Malnutrition, prolonged use of broad-spectrum
antibiotics and fat malabsorption syndrome can prolong the PT/INR.
5. DIC: Prolonged PT/INR results from the consumption of the
coagulation factor in the clotting process.
6. Factor deficiency: Coagulation factors deficiency in the extrinsic
pathway or acquired inhibitors (autoantibodies) of fibrinogen and
factors II, V, VII, or X, or a combined deficiency involving one of these
factors can lead to prolongation of PT/INR
7. Antiphospholipid antibodies: Lupus anticoagulants can prolong the
PT/INR if it has the specificity for factor II (prothrombin). However,
isolated prolongation of the aPTT is more common.
In contrast, shortening of PT usually reflects a technical error in specimen
collection and preparation technique.

Normal and Critical Findings

For normal patients who are not on anticoagulation, the INR is usually 1.0
regardless of the ISI or the particular performing laboratory. For patients who
are on anticoagulant therapy, the therapeutic INR ranges between 2.0 to 3.0.
INR levels above 4.9 are considered critical values and increase the risk of
bleeding. The therapeutic INR range differs in a patient with prosthetic valve:
  For patients with an On-X mechanical bileaflet aortic valve with no
other risk factors for thromboembolism, the INR goal is 2 to 3 for the
first three months after valve surgery; and after three months the goal
is 1.5 to 2.
 For patients with a bileaflet (other than On-X) or current generation,
single-tilting disk, mechanical, aortic, prosthetic valve with no other
risk factors for thromboembolism, the target INR is 2.5.
 For patients with a mechanical aortic prosthetic valve (other than On-
X) and an additional risk factor for thromboembolic events (atrial
fibrillation, previous thromboembolism, left ventricular systolic
dysfunction, or hypercoagulable condition) or an older generation
mechanical aortic valve prosthesis (ball-in-cage), the INR goal is 3.
 For patients with a mechanical mitral prosthetic valve (including On-X
valve) or mechanical tricuspid prosthetic valve, the target INR is 3.

Interfering Factors
Multiple factors that can interfere the INR value are listed below:
Adherence to the VKAs
VKAs are commonly associated with monitoring, and dose adjustments along
with food and drug interactions make the adherence difficult in clinical
practice.
Drug Interactions
Following are the drugs that cause prolongation of INR:
 Antibiotics: especially cotrimoxazole, macrolides, metronidazole, and
fluoroquinolones
 Antifungals: azoles (fluconazole)
 Chemotherapeutics: imatinib, Fluorouracil (5-FU)
 Amiodarone
 Allopurinol
  Serotonin reuptake inhibitors (fluoxetine, sertraline)
Several medications may decrease INR value, for example:
 Antibiotics: Dicloxacillin, nafcillin
 Azathioprine
 Antiepileptics (Carbamazepine, phenobarbital, phenytoin)
 Saint John's Wort
 Vitamin K
Comorbidities
Chronic liver disease may interfere with warfarin dosage, INR value, and
coagulation homeostasis. Acute illness such as infections and gastrointestinal
illnesses may impact the INR control.

Complications
INR level below the target range is associated with increased risk of
thrombosis. Research showed that more than three-fold risk of recurrent
venous thromboembolism is associated with the subtherapeutic INR level.
On the other hand, INR above the therapeutic range is associated with
increased risk of bleeding among which the most concerning condition is an
intracranial hemorrhage. Patients can also present with gastrointestinal
bleeding, hematuria or bleeding from any other site.

Patient Safety and Education

Clinical practice guidelines developed by the American College of Chest
Physicians recommend educating and involving patients on INR testing,
follow up, and result and dosing decisions that increase clinical benefit and
cost-effectiveness. Also, intensive patient education (educating the patients
beyond the usual VKAs information by distributing a pamphlet or by the
primary care provider) has been proposed to reduce adverse events related to
anticoagulation. However, no clinical trial has been conducted to date.
Clinical Significance
Timely INR monitoring and patient-centered education on INR management
is an integral part of patient care. INR management in the therapeutic range
remains a challenge, and hopefully, providers will be able to achieve optimal
outcomes for their patients through clinical practice guidelines.

Questions
To access free multiple choice questions on this topic, click here.

References
1.
Tripathi MM, Egawa S, Wirth AG, Tshikudi DM, Van Cott EM, Nadkarni
SK. Clinical evaluation of whole blood prothrombin time (PT) and
international normalized ratio (INR) using a Laser Speckle Rheology
sensor. Sci Rep. 2017 Aug 23;7(1):9169. [PMC free article:
PMC5569083] [PubMed: 28835607]
2.
Health Quality Ontario. Point-of-Care International Normalized Ratio
(INR) Monitoring Devices for Patients on Long-term Oral
Anticoagulation Therapy: An Evidence-Based Analysis. Ont Health
Technol Assess Ser. 2009;9(12):1-114. [PMC free article: PMC3377545]
[PubMed: 23074516]
3.
Tripathi MM, Egawa S, Wirth AG, Tshikudi DM, Van Cott EM, Nadkarni
SK. Clinical evaluation of whole blood prothrombin time (PT) and
international normalized ratio (INR) using a Laser Speckle Rheology
sensor. Sci Rep. 2017 Aug 23;7(1):9169. [PMC free article:
PMC5569083] [PubMed: 28835607]
4.
Chuang J, Sadler MA, Witt DM. Impact of evacuated collection tube fill
volume and mixing on routine coagulation testing using 2.5-ml
(pediatric) tubes. Chest. 2004 Oct;126(4):1262-6. [PubMed: 15486391]
5.
Barcellona D, Fenu L, Marongiu F. Point-of-care testing INR: an
overview. Clin. Chem. Lab. Med. 2017 May 01;55(6):800-
805. [PubMed: 27754958]
6.
Florkowski C, Don-Wauchope A, Gimenez N, Rodriguez-Capote K, Wils
J, Zemlin A. Point-of-care testing (POCT) and evidence-based
laboratory medicine (EBLM) - does it leverage any advantage in clinical
decision making? Crit Rev Clin Lab Sci. 2017 Nov - Dec;54(7-8):471-
494. [PubMed: 29169287]
7.
Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Fleisher
LA, Jneid H, Mack MJ, McLeod CJ, O'Gara PT, Rigolin VH, Sundt TM,
Thompson A. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC
Guideline for the Management of Patients With Valvular Heart
Disease: A Report of the American College of Cardiology/American
Heart Association Task Force on Clinical Practice
Guidelines. Circulation. 2017 Jun 20;135(25):e1159-e1195. [PubMed:
28298458]
8.
Nordstrom BL, Evans MA, Murphy BR, Nutescu EA, Schein JR, Bookhart
BK. Risk of recurrent venous thromboembolism among deep vein
thrombosis and pulmonary embolism patients treated with
warfarin. Curr Med Res Opin. 2015 Mar;31(3):439-47. [PubMed:
25495136]
9.
 Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ,
Svensson PJ, Veenstra DL, Crowther M, Guyatt GH. Evidence-based
management of anticoagulant therapy: Antithrombotic Therapy and
Prevention of Thrombosis, 9th ed: American College of Chest
Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012
Feb;141(2 Suppl):e152S-e184S. [PMC free article: PMC3278055]
[PubMed: 22315259]

Copyright © 2018, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution 4.0 International License

(http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution, and reproduction in

any medium or format, as long as you give appropriate credit to the original author(s) and the source, a link is provided to

the Creative Commons license, and any changes made are indicated.

Bookshelf ID: NBK507707PMID: 29939529